Roche's pricey new breast-cancer combo barely beats old drug – The Boston Globe
Fortune |
Roche’s pricey new breast-cancer combo barely beats old drug
The Boston Globe Roche Holding’s new breast cancer combination therapy barely outperformed a current gold-standard drug for the disease — the company’s own decades-old Herceptin — in its latest study. The results, presented Monday in Chicago at the world’s largest … Roche combo of breast cancer drugs shows modest benefit Roche Loses Billions in Value After Pricey Breast Cancer Drug Combo Disappoints Roche Drug Helps Keep Breast Cancer In Remission, But Tiny Benefit Stokes Hopes For Rival, Puma |
View original article
Author:
Powered by WPeMatico
Health Topic Contributor
Editors and curators bringing you the latest and most impactful health news. Truly objective, we print links to stories and studies that may contradict one another. If you're searching for news on health studies, alternative health modalities, facts on modern allopathic medicine, and more, we're you're team bringing you the stories and facts that matter.